Mayne Pharma Group Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Mayne Pharma Group Limited with three other
pharmaceutical manufacturers in Australasia:
sales of 79.09 million Australian Dollars [US$47.13 million]
AFT Pharmaceuticals Ltd
of NEW ZEALAND
(85.13 million New Zealand Dollars [US$49.78 million]
of which 59%
was Australia), and
Palla Pharma Ltd
(54.84 million Australian Dollars [US$32.68 million]
of which 85%
During the year ended June of 2019, sales at
Mayne Pharma Group Limited were A$526.22 million (US$313.60 million).
decrease of 0.8%
versus 2018, when the company's sales were A$530.43 million.
Contributing to the drop in overall sales was the 16.8% decline
in Generic Products, from A$385.70 million to A$320.77 million.
However, these declines were partially offset by the increase in sales of
Specialty Brands (up 104.9% to A$91.56 million)
Metrics Contract Services (Mcs) (up 14.5% to A$72.20 million)
Mayne Pharma International (Mpi) (up 10.4% to A$40.68 million)